AT & S Austria Technologie & Systemtechnik (ATS) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
9 Jan, 2026Executive summary
Revenue for the first three quarters of 2024/25 was stable at €1,197 million, down 1% year-over-year, with adjusted EBITDA margin improvement driven by cost reduction initiatives.
The sale of the Ansan/AT&S Korea plant was finalized on January 31, 2025, providing significant cash inflow and strengthening the group's strategic profile.
Leadership transition included the appointment of Dr. Riedl as Chairman, with a new CEO announcement pending.
Cost optimization and efficiency programs intensified, achieving €80 million in sustainable savings by December 2024 and targeting further reductions, including up to 1,000 job cuts.
Financial highlights
Adjusted EBITDA for Q1-3 2024/25 increased by 3.5% to €331.9 million, with margin up to 27.7%; reported EBITDA fell due to non-recurring expenses and higher start-up costs.
Net loss for Q1-3 2024/25 was €-95.3 million, mainly due to higher financing costs, increased depreciation, and lower EBITDA.
Net CAPEX reduced by 53% year-over-year to €327.5 million.
Cash and cash equivalents plus unused credit lines totaled €685 million as of December 31, 2024.
Net debt increased 18% to €1,655 million; equity ratio rose slightly to 20.9%.
Outlook and guidance
FY 2024/25 revenue expected at €1.5–1.6 billion, with adjusted EBITDA margin of 24–26%, excluding start-up and one-off costs.
Net CAPEX for FY 2024/25 projected just under €500 million.
Mid-term (FY 2026/27) revenue guidance lowered to €2.1–2.4 billion, with EBITDA margin forecast at 24–28%.
High-volume production at new plants in Kulim and Leoben delayed by 1–2 quarters, with revenue contributions expected in Q1 2025/26.
Net debt/EBITDA targeted below 3 post-Ansan sale, with temporary exceedance possible.
Latest events from AT & S Austria Technologie & Systemtechnik
- Revenue up 10% to €1.314B, EBITDA margin 23%, strong outlook despite FX and supply risks.ATS
Q3 20263 Feb 2026 - Adjusted EBITDA margin rose to 27.6% despite revenue decline and net loss.ATS
Q1 20252 Feb 2026 - Revenue, EBITDA, and cash flow improved, but FX and supply chain risks persist.ATS
Q2 202616 Dec 2025 - Revenue up 3%, EBITDA margin at 26%, with major investments and cost savings; outlook cautious.ATS
Q4 202521 Nov 2025 - Revenue up 14.2% year-over-year, but net loss widened on FX and ramp-up costs.ATS
Q1 202616 Nov 2025 - Revenue and earnings fell amid price pressure, but mid-term growth targets are reaffirmed.ATS
Q2 202513 Jun 2025